Delivery MethodVIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTEDProduct:DrugsRecipient:Med Shop Inc / www.medshopinc.comNetherlandsinfo@medshopinc.comIssuing Office:Center for Drug Evaluation and Research (CDER)United StatesWARNING LETTERReference Number: MARCS-CMS 725157To Med Shop Inc:This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website www.medshopinc.com. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that you comply with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.As discussed below, FDA has observed that www.medshopinc.com introduces into interstate commerce unapproved and misbranded ketamine drug products, including certain drugs for which the FDA-approved version is an injectable or subject to a Risk Evaluation and Mitigation Strategy (REMS).1 FDA has identified significant risks associated with unapproved ketamine products, especially in the absence of appropriate medical supervision. Given the increased interest in the use of ketamine products, the easy availability of unapproved and misbranded ketamine products via the internet puts U.S. consumers at risk for serious adverse events. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body's natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis.There are also inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.Accordingly, FDA requests that www.medshopinc.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm.FDA ReviewViolations were identified and documented during a review of your website www.medshopinc.com, FDA Establishment Identifier (FEI) 3043544193, on February 27, 2026.Violations of the Federal Food, Drug, and Cosmetic ActOn your website at internet address www.medshopinc.com, you introduce into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), 301(d), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 331(a), 331(d), 352(f)(1), 353(b)(1), and 355(a)).The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.Unapproved New Drug ViolationsCertain products offered for sale by www.medshopinc.com are drugs within the meaning of section 201(g) of the FD&C Act (21 U.S.C. 321(g)) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body. These drugs are also new drugs as defined by section 201(p) of the FD&C Act (21 U.S.C. 321(p)), because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act.You failed to obtain approved applications pursuant to section 505 of the FD&C Act (21 U.S.C. 355) for these products that you have introduced into interstate commerce. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act.An example of an unapproved ketamine drug product you offer for sale on www.medshopinc.com is esketamine marketed as "Ketamine Nasal Spray." Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 Code of Federal Regulations (CFR) 201.128) includes the claim "Ketamine Nasal Spray is a powerful treatment option designed for individuals suffering from treatment-resistant depression and chronic pain. Administered as a nasal spray, it offers rapid relief by acting on NMDA receptors in the brain."While there are FDA-approved versions of ketamine drug products on the market in the United States, there is no approved drug application pursuant to section 505 of the FD&C Act in effect for "Ketamine Nasal Spray” offered by www.medshopinc.com.FDA-approved ketamine, including products marketed under the brand name KETALAR, is a Schedule III controlled substance. It is an intravenous or intramuscular injection indicated as a general anesthetic, including as a sole agent or as an adjunct to other anesthetic agents, for the induction of anesthesia and for diagnostic and surgical procedures. Ketamine is a racemic mixture consisting of two mirror image molecules, R- and S-ketamine (arketamine and esketamine, respectively). This product is only available pursuant to a prescription from a licensed practitioner. Ketamine is not FDA-approved for the treatment of any psychiatric disorder.FDA-approved esketamine, a ketamine derivative, is a Schedule III controlled substance marketed under the brand name SPRAVATO. It is a nasal spray indicated for treatment-resistant depression in adults and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in conjunction with an oral antidepressant. Furthermore, FDA-approved SPRAVATO bears a boxed warning, commonly referred to as a "black box warning," which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses the risk for sedation, dissociation, and respiratory depression after administration; the potential for abuse and misuse; the increased risk of suicidal thoughts and behaviors in pediatric and young adult patients taking antidepressants; and the requirement that SPRAVATO be available only through a restricted program, the SPRAVATO REMS, because of the risks of serious adverse outcomes from sedation, dissociation, respiratory depression, abuse, and misuse. The SPRAVATO REMS requires SPRAVATO to be dispensed and administered in medically supervised health care settings that are certified in the REMS and monitor patients for a minimum of two hours following administration. In addition, pharmacies must be certified in the REMS and must only dispense SPRAVATO to health care settings that are certified in the program.Misbranded Drug ViolationsA drug is misbranded under section 502(f)(1) of the FD&C Act if its labeling fails to bear adequate directions for use. "Adequate directions for use" means directions under which a layperson can use a drug safely and for the purposes for which it is intended (see 21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1) of the FD&C Act include those that, because of their toxicity or other potentiality for harmful effect, or the method of their use, or the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act (21 U.S.C. 353(b)(1)(A)), can be used safely only at the direction, and under the supervision, of a licensed practitioner.You failed to bear adequate directions for use on the labeling for this drug product that you have introduced into interstate commerce. Because the aforementioned drug is a prescription drug intended for conditions that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use the product safely for their intended use. Consequently, the labeling for this drug product fails to bear adequate directions for use, causing it to be misbranded under section 502(f)(1) of the FD&C Act. Because this drug is not approved in the United States, it is also not exempt under 21 CFR 201.115(a) from the requirements of section 502(f)(1) of the FD&C Act. By offering this drug for sale to U.S. consumers, www.medshopinc.com is causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&C Act.ConclusionAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.Send your written response to FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov within 15 business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your written response with reference number “MARCS-CMS 725157” in the subject line of the email.If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.Please note FDA posts warning letters on www.fda.gov.Sincerely,/S/Sangeeta Vaswani Chatterjee, PharmDDirectorOffice of Drug Security, Integrity, and ResponseOffice of ComplianceCenter for Drug Evaluation and ResearchU.S. Food and Drug Administration_____________________1 REMS refers to a drug safety program that FDA can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks. See the Risk Evaluation and Mitigation Strategies website at https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems.

Delivery Method:Via EmailProduct:Food & BeveragesRecipient:Todd J. BushmanCEOBushman Organic Farms, Inc.1402 Highway 150Calmar, IA 52132-7608United StatesIssuing Office:Human Foods ProgramUnited StatesWARNING LETTERRe: CMS # 729451Dear Mr. Todd J. BushmanOn August 15 – September 27, 2023, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Bushman Organic Farms, Inc. located at 1402 Highway 150 Calmar, IA 52132-7608. We also conducted an inspection on March 17 – March 27, 2026. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.The FSVP regulation requires that importers perform certain risk-based activities to verify that human and/or animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https://www.fda.gov/food/food-safety-modernization-act-fsma/fsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We have not received your response to the Form FDA 483a issued on March 27, 2026.Your significant violations of the FSVP regulation are as follows:You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:Organic soybean meal imported from (b)(4), located in (b)(4)Organic soybean meal imported from (b)(4), located in (b)(4)Organic soybean meal imported from (b)(4), located in (b)(4)Organic soybean meal imported from (b)(4) located in (b)(4)Organic soybean meal imported from (b)(4) located in (b)(4)Organic soybean meal imported from (b)(4) located in (b)(4)Organic soybean meal imported from (b)(4) located in (b)(4)Organic soybean meal imported from (b)(4) located in (b)(4)Organic soybean meal imported from (b)(4) located in (b)(4)Organic soybean meal imported from (b)(4) located in (b)(4)Organic soybean meal imported from (b)(4) located in (b)(4)The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.(b)(3)(A)As a responsible official of a facility that manufactures/processes, packs, or holds food for human or animal consumption in the United States, you are responsible for ensuring that your overall operation and the products you distribute are in compliance with the law.(b)(3)(A)This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http://www.accessdata.fda.gov/cms_ia/ialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.Please send your reply to Food and Drug Administration, Attention: Brian Erickson, Compliance Officer, 9777 Via de la Amistad, Suite 131, San Diego, CA 92154. If you have any questions regarding this letter, or wish to send your response electronically, you may contact Brian Erickson via email at brian.erickson@fda.hhs.gov. Please reference CMS # 729451 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.Sincerely,/S/Todd CatoProgram Division DirectorDivision of Southwest ImportsOne Main Place1201 Main Street, Suite 7200Dallas, TX 75202

为优化营商环境，提升药监政务服务效能，助推全区医药产业高质量发展，近日，自治区药监局深化“互联网+药监政务服务”，依托智慧药监建设，在局“互联网+政务服务”平台开设“企业服务需求”专栏，搭建“两品一械”企业专属线上需求收集平台。平台整合原有诉求渠道，统一线上服务入口，畅通企业诉求反馈渠道，构建“线上一键申报、后台分类分流、技术专班帮扶、限时闭环办结、全程溯源反馈”全链条服务体系，推动服务更加智能、精细、常态。一是全域覆盖，申报便捷高效。平台面向全区药品、医疗器械、化妆品企业开放。企业可登录内蒙古自治区药品监督管理局门户网站或“内蒙古药监”公众号，通过“办事服务”栏目跳转至自治区政务服务网，通过个人登录/法人登录后，在“互联网+政府服务”平台的“其他申报办理”模块进入“企业服务需求”端口，按指引即可提交诉求。企业可全天线上申报审批咨询、技术帮扶、政策解读、合规疑问、发展难题及产业建议等事项，同步支持上传佐证材料，全程零跑腿、免重复填报，有效解决传统渠道分散、响应滞后的问题，实现企业诉求“全天候、零距离、线上办”。二是精准分流，专人专班处置。建立诉求智能分类处置机制，按药械、化妆品、蒙医药、审批服务、监管合规、产业政策等维度分类标注，结合人工复核精准分派至对应业务部门或技术审评部门。明确责任人、办理标准和办结时限，实行简单咨询即时答复、常规诉求限时办结、疑难问题统筹会商、复杂事项联动处置，依托全局技术力量开展一对一精准帮扶，坚决杜绝诉求积压、推诿拖延。三是全程可溯，闭环落地见效。平台实现诉求办理全流程公开透明，企业可实时查询流转节点、办理进度和处置结果。对办结事项统一归档留存，常态化开展企业回访，核验办理质效、收集后续需求，形成“收集—处置—反馈—提质”完整闭环，确保企业诉求事事有回应、件件有落实。四是数据赋能，精准施策发力。依托平台大数据分析能力，定期梳理企业高频诉求、共性难题和产业堵点，精准研判医药产业发展痛点及政策落地难点，为惠企政策优化、监管服务升级、产业精准招商、重点项目培育提供数据支撑。以数字化赋能药监服务提质增效，持续激发产业发展活力，切实提升企业获得感和营商环境满意度。

企业名称辽宁恒瑞医药连锁有限公司企业类型药品零售连锁总部检查时间2026年6月9日-2026年6月11日所在地市辽阳市检查依据《药品管理法》《药品经营质量管理规范》《药品经营和使用质量监督管理办法》等法律、法规。检查事项药品经营检查检查方式常规检查；专项检查。检查内容1.执行GSP情况； 2.辽宁省药品经营环节“清源”巩固提升行动专项检查。存在问题在人员与培训方面存在个别培训内容不全等问题；在收货与验收方面存在部分药品验收记录内容不全等问题。处理措施限期整改。整改情况已按要求完成整改。

Delivery Method:VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTEDProduct:DrugsRecipient:Buy Keta Online / www.buyketaonline.comUnited Statesinfo@buyketaonline.comIssuing Office:Center for Drug Evaluation and Research (CDER)United StatesJune 23, 2026WARNING LETTERReference Number: MARCS-CMS 725145To Buy Keta Online:This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website www.buyketaonline.com. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that you comply with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.As discussed below, FDA has observed that www.buyketaonline.com introduces into interstate commerce unapproved and misbranded ketamine drug products, including certain drugs for which the FDA-approved version is an injectable or subject to a Risk Evaluation and Mitigation Strategy (REMS).1 FDA has identified significant risks associated with unapproved ketamine products, especially in the absence of appropriate medical supervision. Given the increased interest in the use of ketamine products, the easy availability of unapproved and misbranded ketamine products via the internet puts U.S. consumers at risk for serious adverse events. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body's natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis.There are also inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.Accordingly, FDA requests that www.buyketaonline.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm.FDA ReviewViolations were identified and documented during a review of your website www.buyketaonline.com, FDA Establishment Identifier (FEI) 3043544005, on March 2, 2026.Violations of the Federal Food, Drug, and Cosmetic ActOn your website at internet address www.buyketaonline.com, you introduce into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), 301(d), 301(k), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 331(a), 331(d), 331(k), 352(f)(1), 353(b)(1), and 355(a)).The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.Unapproved New Drug ViolationsDrugs Introduced or Delivered for Introduction into Interstate Commerce Without an Approved Application in Violation of Sections 505(a) and 301(d) of the FD&C ActCertain products offered for sale by www.buyketaonline.com are drugs within the meaning of section 201(g) of the FD&C Act (21 U.S.C. 321(g)) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body. These drugs are also new drugs as defined by section 201(p) of the FD&C Act (21 U.S.C. 321(p)), because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act.You failed to obtain approved applications pursuant to section 505 of the FD&C Act (21 U.S.C. 355) for these products that you have introduced into interstate commerce. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act.An example of an unapproved ketamine drug product you offer for sale on www.buyketaonline.com is ketamine marketed as "Buy Ketamine Liquid Online." Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 Code of Federal Regulations (CFR) 201.128) includes the claims "Our pharmaceutical-grade ketamine solution is trusted for research, pain management studies, and medical-assisted therapy" and "Ketamine is a rapid-acting general anesthetic that has significant analgesic activity . . . ."While there are FDA-approved versions of ketamine drug products on the market in the United States, there are no approved drug applications pursuant to section 505 of the FD&C Act in effect for "Buy Ketamine Liquid Online" offered by www.buyketaonline.com.FDA-approved ketamine, including products marketed under the brand name KETALAR, is a Schedule III controlled substance. It is an intravenous or intramuscular injection indicated as a general anesthetic, including as a sole agent or as an adjunct to other anesthetic agents, for the induction of anesthesia and for diagnostic and surgical procedures. Ketamine is a racemic mixture consisting of two mirror image molecules, R- and S-ketamine (arketamine and esketamine, respectively). This product is only available pursuant to a prescription from a licensed practitioner. Ketamine is not FDA-approved for the treatment of any psychiatric disorder.FDA-approved esketamine, a ketamine derivative, is a Schedule III controlled substance marketed under the brand name SPRAVATO. It is a nasal spray indicated for treatment-resistant depression in adults and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in conjunction with an oral antidepressant. Furthermore, FDA-approved SPRAVATO bears a boxed warning, commonly referred to as a "black box warning," which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses the risk for sedation, dissociation, and respiratory depression after administration; the potential for abuse and misuse; the increased risk of suicidal thoughts and behaviors in pediatric and young adult patients taking antidepressants; and the requirement that SPRAVATO be available only through a restricted program, the SPRAVATO REMS, because of the risks of serious adverse outcomes from sedation, dissociation, respiratory depression, abuse, and misuse. The SPRAVATO REMS requires SPRAVATO to be dispensed and administered in medically supervised health care settings that are certified in the REMS and monitor patients for a minimum of two hours following administration. In addition, pharmacies must be certified in the REMS and must only dispense SPRAVATO to health care settings that are certified in the program.Compounded Drug Products Not Eligible for the Exemptions Under Sections 503A and 503B of the FD&C Act and Therefore Also in Violation of Sections 505(a) and 301(d) of the FD&C ActSection 503A of the FD&C Act (21 U.S.C. 353a) describes the conditions under which human drug products compounded by a licensed pharmacist in a State-licensed pharmacy or a Federal facility, or a licensed physician, qualify for exemptions from three sections of the FD&C Act: compliance with current good manufacturing practice of section 501(a)(2)(B) (21 U.S.C. 351(a)(2)(B)); labeling with adequate directions for use of section 502(f)(1); and FDA approval prior to marketing of section 505.2Section 503B of the FD&C Act (21 U.S.C. 353b) describes the conditions under which human drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from three sections of the FD&C Act: labeling with adequate directions for use of section 502(f)(1); FDA approval prior to marketing of section 505; and the Drug Supply Chain Security Act requirements in section 582 (21 U.S.C. 360eee-1).3You failed to meet the conditions of sections 503A and 503B of the FD&C Act.An example of an unapproved compounded ketamine drug product you offer for sale on www.buyketaonline.com is ketamine marketed as "ketamine capsules for depression." Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 CFR 201.128) includes the claim "Our ketamine capsules for depression provide a professionally compounded, fast-acting option for individuals seeking relief from major depressive disorder, anxiety, and treatment-resistant depression."A second example of an unapproved compounded ketamine drug product you offer for sale on www.buyketaonline.com is esketamine marketed as “Buy ketamine [sic] Nasal Spray.” Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 CFR 201.128) includes the claim “Ketamine nasal spray acts by blocking receptors in the brain called NMDA receptors. The blockade of these receptors leads to increased mTOR pathway signaling, increased AMPA receptor activation, and increased development and efficacy of synapses in the brain, leading to an anti-depressant effect.”Your operation permits the purchase of "ketamine capsules for depression" and “Buy ketamine [sic] Nasal Spray” that have not been compounded pursuant to a prescription. Receipt of prescriptions for individually identified patients for drug products compounded by licensed pharmacists in State-licensed pharmacies and Federal facilities, or by licensed physicians is a condition necessary to qualify for the exemptions under section 503A of the FD&C Act. In addition, your operation is not a registered outsourcing facility, and therefore, any drug products produced by your operation do not qualify for the exemptions under section 503B of the FD&C Act. Further, section 503B of the FD&C Act includes a condition that states a drug compounded by an outsourcing facility "will not be sold or transferred by an entity other than the outsourcing facility that compounded such drug."4 Because your “ketamine capsules for depression” and “Buy ketamine [sic] Nasal Spray” does not meet the conditions of either section 503A or section 503B of the FD&C Act, they are not eligible for the exemptions of those sections, including FDA approval requirements of section 505 of the FD&C Act.There are no FDA-approved applications in effect for your “ketamine capsules for depression” and “Buy ketamine [sic] Nasal Spray.” Under sections 505(a) and 301(d) of the FD&C Act a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FD&C Act is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FD&C Act.Misbranded Drug ViolationsA drug is misbranded under section 502(f)(1) of the FD&C Act if its labeling fails to bear adequate directions for use. "Adequate directions for use" means directions under which a layperson can use a drug safely and for the purposes for which it is intended (see 21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1) of the FD&C Act include those that, because of their toxicity or other potentiality for harmful effect, or the method of their use, or the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act (21 U.S.C. 353(b)(1)(A)), can be used safely only at the direction, and under the supervision, of a licensed practitioner.You failed to bear adequate directions for use on the labeling for these drug products that you have introduced into interstate commerce. Because the aforementioned drugs are prescription drugs intended for conditions that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use the products safely for their intended use. Consequently, the labeling for these drug products fails to bear adequate directions for use, causing them to be misbranded under section 502(f)(1) of the FD&C Act. Because these drugs are not approved in the United States, they are also not exempt under 21 CFR 201.115(a) from the requirements of section 502(f)(1) of the FD&C Act. In addition, because your compounded drug products do not meet the conditions of sections 503A or 503B of the FD&C Act they are also not exempt from section 502(f)(1) of the FD&C Act. By offering these drugs for sale to U.S. consumers, www.buyketaonline.com is causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&C Act.Furthermore, under U.S. law, prescription drugs can be dispensed only pursuant to a prescription from a health care practitioner licensed by law to administer prescription drugs. By offering the aforementioned drug products without requiring a prescription, www.buyketaonline.com jeopardizes patient safety and misbrands the drug products under section 503(b)(1) of the FD&C Act. Dispensing a prescription drug without a prescription is an act which results in the drug being misbranded while held for sale, in violation of section 301(k) of the FD&C Act.ConclusionAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.Send your written response to FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov within 15 business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your written response with reference number “MARCS-CMS 725145” in the subject line of the email.If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.Please note FDA posts warning letters on www.fda.gov.Sincerely,/S/Sangeeta Vaswani Chatterjee, PharmDDirectorOffice of Drug Security, Integrity, and ResponseOffice of ComplianceCenter for Drug Evaluation and ResearchU.S. Food and Drug Administration/S/Matthew J. Lash, JDActing DirectorOffice of Compounding Quality and ComplianceOffice of ComplianceCenter for Drug Evaluation and ResearchU.S. Food and Drug Administration_________________________1 REMS refers to a drug safety program that FDA can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks. See the Risk Evaluation and Mitigation Strategies website at https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems.2 We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FD&C Act.3 We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FD&C Act.4 Section 503B(a)(8) of the FD&C Act (21 U.S.C. 353b(a)(8)) does not prohibit administration of the drug in a health care setting or dispensing a drug pursuant to a prescription executed in accordance with section 503(b)(1) of the FD&C Act.

Delivery Method:VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTEDProduct:DrugsRecipient:Ketamine Troche Store / www.ketaminetrochestore.comUnited Statescontact@ketaminetrochestore.comIssuing Office:Center for Drug Evaluation and Research (CDER)United StatesJune 23, 2026WARNING LETTERReference Number: MARCS-CMS 722122To Ketamine Troche Store:This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website www.ketaminetrochestore.com. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that you comply with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.As discussed below, FDA has observed that www.ketaminetrochestore.com introduces into interstate commerce unapproved and misbranded ketamine drug products, including certain drugs for which the FDA-approved version is an injectable or subject to a Risk Evaluation and Mitigation Strategy (REMS).1 FDA has identified significant risks associated with unapproved ketamine products, especially in the absence of appropriate medical supervision. Given the increased interest in the use of ketamine products, the easy availability of unapproved and misbranded ketamine products via the internet puts U.S. consumers at risk for serious adverse events. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body's natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis.There are also inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.Accordingly, FDA requests that www.ketaminetrochestore.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm.FDA ReviewViolations were identified and documented during a review of your website www.ketaminetrochestore.com, FDA Establishment Identifier (FEI) 3042658413, from January 9 to January 16, 2026.Violations of the Federal Food, Drug, and Cosmetic ActOn your website at internet address www.ketaminetrochestore.com, you introduce into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), 301(d), 301(k), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 331(a), 331(d), 331(k), 352(f)(1), 353(b)(1), and 355(a)).The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.Unapproved New Drug ViolationsDrugs Introduced or Delivered for Introduction into Interstate Commerce Without an Approved Application in Violation of Sections 505(a) and 301(d) of the FD&C ActCertain products offered for sale by www.ketaminetrochestore.com are drugs within the meaning of section 201(g) of the FD&C Act (21 U.S.C. 321(g)) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body. These drugs are also new drugs as defined by section 201(p) of the FD&C Act (21 U.S.C. 321(p)), because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act.You failed to obtain approved applications pursuant to section 505 of the FD&C Act (21 U.S.C. 355) for these products that you have introduced into interstate commerce. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act.An example of an unapproved ketamine drug product you offer for sale on www.ketaminetrochestore.com is ketamine marketed as "Ketamine Liquid." Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 Code of Federal Regulations (CFR) 201.128) includes the claim "Ketamine liquid is revolutionizing the way we treat mental health conditions and manage pain. Whether it's used for anesthesia, depression treatment, or chronic pain relief, ketamine liquid offers rapid and effective results."A second example of an unapproved ketamine drug product you offer for sale on www.ketaminetrochestore.com is ketamine marketed as "Ketamine Suppository." Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 CFR 201.128) includes the claim "Ketamine suppository which is a rectally administered form of ketamine is emerging as a promising alternative for individuals seeking to find relief in chronic pain, treatment-resistant depression (TRD) and other medical conditions."A third example of an unapproved ketamine drug product you offer for sale on www.ketaminetrochestore.com is esketamine marketed as "Ketamine Nasal Spray." Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 CFR 201.128) includes the claims "Ketamine is a breakthrough in modern medicine offering a fast and effective solution for treating various mental health conditions, particulary [sic] depression and anxiety" and "can also be used to treat anxiety problems that don't respond to traditional therapy."While there are FDA-approved versions of ketamine drug products on the market in the United States, there are no approved drug applications pursuant to section 505 of the FD&C Act in effect for "Ketamine Liquid," "Ketamine Suppository," and "Ketamine Nasal Spray" offered by www.ketaminetrochestore.com.FDA-approved ketamine, including products marketed under the brand name KETALAR, is a Schedule III controlled substance. It is an intravenous or intramuscular injection indicated as a general anesthetic, including as a sole agent or as an adjunct to other anesthetic agents, for the induction of anesthesia and for diagnostic and surgical procedures. Ketamine is a racemic mixture consisting of two mirror image molecules, R- and S-ketamine (arketamine and esketamine, respectively). This product is only available pursuant to a prescription from a licensed practitioner. Ketamine is not FDA-approved for the treatment of any psychiatric disorder.FDA-approved esketamine, a ketamine derivative, is a Schedule III controlled substance marketed under the brand name SPRAVATO. It is a nasal spray indicated for treatment-resistant depression in adults and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in conjunction with an oral antidepressant. Furthermore, FDA-approved SPRAVATO bears a boxed warning, commonly referred to as a "black box warning," which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses the risk for sedation, dissociation, and respiratory depression after administration; the potential for abuse and misuse; the increased risk of suicidal thoughts and behaviors in pediatric and young adult patients taking antidepressants; and the requirement that SPRAVATO be available only through a restricted program, the SPRAVATO REMS, because of the risks of serious adverse outcomes from sedation, dissociation, respiratory depression, abuse, and misuse. The SPRAVATO REMS requires SPRAVATO to be dispensed and administered in medically supervised health care settings that are certified in the REMS and monitor patients for a minimum of two hours following administration. In addition, pharmacies must be certified in the REMS and must only dispense SPRAVATO to health care settings that are certified in the program.Compounded Drug Products Not Eligible for the Exemptions Under Sections 503A and 503B of the FD&C Act and Therefore Also in Violation of Sections 505(a) and 301(d) of the FD&C ActSection 503A of the FD&C Act (21 U.S.C. 353a) describes the conditions under which human drug products compounded by a licensed pharmacist in a State-licensed pharmacy or a Federal facility, or a licensed physician, qualify for exemptions from three sections of the FD&C Act: compliance with current good manufacturing practice of section 501(a)(2)(B) (21 U.S.C. 351(a)(2)(B)); labeling with adequate directions for use of section 502(f)(1); and FDA approval prior to marketing of section 505.2Section 503B of the FD&C Act (21 U.S.C. 353b) describes the conditions under which human drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from three sections of the FD&C Act: labeling with adequate directions for use of section 502(f)(1); FDA approval prior to marketing of section 505; and the Drug Supply Chain Security Act requirements in section 582 (21 U.S.C. 360eee-1).3You failed to meet the conditions of sections 503A and 503B of the FD&C Act.An example of an unapproved compounded ketamine drug product you offer for sale on www.ketaminetrochestore.com is ketamine marketed as "Ketamine 100 mg Troche." Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 CFR 201.128) includes the claim "Ketamine Troches 100mg is a carefully formulated drug used to treat a wide range of diseases, including chronic pain, depression, anxiety, and other mental health issues."Your operation permits the purchase of "Ketamine 100 mg Troche" that has not been compounded pursuant to a prescription. Receipt of prescriptions for individually identified patients for drug products compounded by licensed pharmacists in State-licensed pharmacies and Federal facilities, or by licensed physicians is a condition necessary to qualify for the exemptions under section 503A of the FD&C Act. In addition, your operation is not a registered outsourcing facility, and therefore, any drug products produced by your operation do not qualify for the exemptions under section 503B of the FD&C Act. Further, section 503B of the FD&C Act includes a condition that states a drug compounded by an outsourcing facility "will not be sold or transferred by an entity other than the outsourcing facility that compounded such drug."4 Because your “Ketamine 100 mg Troche” does not meet the conditions of either section 503A or section 503B of the FD&C Act, it is not eligible for the exemptions of those sections, including FDA approval requirements of section 505 of the FD&C Act.There are no FDA-approved applications in effect for your “Ketamine 100 mg Troche.” Under sections 505(a) and 301(d) of the FD&C Act a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FD&C Act is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FD&C Act.Misbranded Drug ViolationsA drug is misbranded under section 502(f)(1) of the FD&C Act if its labeling fails to bear adequate directions for use. "Adequate directions for use" means directions under which a layperson can use a drug safely and for the purposes for which it is intended (see 21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1) of the FD&C Act include those that, because of their toxicity or other potentiality for harmful effect, or the method of their use, or the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act (21 U.S.C. 353(b)(1)(A)), can be used safely only at the direction, and under the supervision, of a licensed practitioner.You failed to bear adequate directions for use on the labeling for these drug products that you have introduced into interstate commerce. Because the aforementioned drugs are prescription drugs intended for conditions that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use the products safely for their intended use. Consequently, the labeling for these drug products fails to bear adequate directions for use, causing them to be misbranded under section 502(f)(1) of the FD&C Act. Because these drugs are not approved in the United States, they are also not exempt under 21 CFR 201.115(a) from the requirements of section 502(f)(1) of the FD&C Act. In addition, because your compounded drug products do not meet the conditions of sections 503A or 503B of the FD&C Act, they are also not exempt from section 502(f)(1) of the FD&C Act. By offering these drugs for sale to U.S. consumers, www.ketaminetrochestore.com is causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&C Act.Furthermore, under U.S. law, prescription drugs can be dispensed only pursuant to a prescription from a health care practitioner licensed by law to administer prescription drugs. By offering the aforementioned drug products without requiring a prescription, www.ketaminetrochestore.com jeopardizes patient safety and misbrands the drug products under section 503(b)(1) of the FD&C Act. Dispensing a prescription drug without a prescription is an act which results in the drug being misbranded while held for sale, in violation of section 301(k) of the FD&C Act.ConclusionAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.Send your written response to FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov within 15 business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your written response with reference number “MARCS-CMS 722122” in the subject line of the email.If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.Please note FDA posts warning letters on www.fda.gov.Sincerely,/S/Sangeeta Vaswani Chatterjee, PharmDDirectorOffice of Drug Security, Integrity, and ResponseOffice of ComplianceCenter for Drug Evaluation and ResearchU.S. Food and Drug Administration/S/Matthew J. Lash, JDActing DirectorOffice of Compounding Quality and ComplianceOffice of ComplianceCenter for Drug Evaluation and ResearchU.S. Food and Drug Administration________________________1 REMS refers to a drug safety program that FDA can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks. See the Risk Evaluation and Mitigation Strategies website at https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems.2 We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FD&C Act.3 We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FD&C Act.4 Section 503B(a)(8) of the FD&C Act (21 U.S.C. 353b(a)(8)) does not prohibit administration of the drug in a health care setting or dispensing a drug pursuant to a prescription executed in accordance with section 503(b)(1) of the FD&C Act.

Delivery Method:VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTEDProduct:DrugsRecipient:ketaminetroches.comUnited Statessales@ketaminetroches.comIssuing Office:Center for Drug Evaluation and Research (CDER)United StatesJune 23, 2026WARNING LETTERReference Number: MARCS-CMS 725148To ketaminetroches.com:This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website www.ketaminetroches.com. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that you comply with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.As discussed below, FDA has observed that www.ketaminetroches.com introduces into interstate commerce unapproved and misbranded ketamine drug products, including certain drugs for which the FDA-approved version is an injectable or subject to a Risk Evaluation and Mitigation Strategy (REMS).1 FDA has identified significant risks associated with unapproved ketamine products, especially in the absence of appropriate medical supervision. Given the increased interest in the use of ketamine products, the easy availability of unapproved and misbranded ketamine products via the internet puts U.S. consumers at risk for serious adverse events. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body's natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis.There are also inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.Accordingly, FDA requests that www.ketaminetroches.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm.FDA ReviewViolations were identified and documented during a review of your website www.ketaminetroches.com, FDA Establishment Identifier (FEI) 3043544217, on February 25, 2026.Violations of the Federal Food, Drug, and Cosmetic ActOn your website at internet address www.ketaminetroches.com, you introduce into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), 301(d), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 331(a), 331(d), 352(f)(1), 353(b)(1), and 355(a)).The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.Unapproved New Drug ViolationsCertain products offered for sale by www.ketaminetroches.com are drugs within the meaning of section 201(g) of the FD&C Act (21 U.S.C. 321(g)) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body. These drugs are also new drugs as defined by section 201(p) of the FD&C Act (21 U.S.C. 321(p)), because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act.You failed to obtain approved applications pursuant to section 505 of the FD&C Act (21 U.S.C. 355) for these products that you have introduced into interstate commerce. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act.An example of an unapproved ketamine drug product you offer for sale on www.ketaminetroches.com is ketamine marketed as "Ketamine Troches." Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 CFR 201.128) includes the claim "Ketamine troches have emerged as a groundbreaking form of psychotherapy, offering renewed hope and healing for individuals navigating the complexities of mental health challenges. These innovative lozenges infused with a carefully measured dose of ketamine—an FDA-approved anesthetic and dissociative agent—hold immense potential in the treatment of conditions such as anxiety, depression . . . ."While there are FDA-approved versions of ketamine drug products on the market in the United States, there are no approved drug applications pursuant to section 505 of the FD&C Act in effect for "Ketamine Troches” offered by www.ketaminetroches.com.FDA-approved ketamine, including products marketed under the brand name KETALAR, is a Schedule III controlled substance. It is an intravenous or intramuscular injection indicated as a general anesthetic, including as a sole agent or as an adjunct to other anesthetic agents, for the induction of anesthesia and for diagnostic and surgical procedures. Ketamine is a racemic mixture consisting of two mirror image molecules, R- and S-ketamine (arketamine and esketamine, respectively). This product is only available pursuant to a prescription from a licensed practitioner. Ketamine is not FDA-approved for the treatment of any psychiatric disorder.FDA-approved esketamine, a ketamine derivative, is a Schedule III controlled substance marketed under the brand name SPRAVATO. It is a nasal spray indicated for treatment-resistant depression in adults and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in conjunction with an oral antidepressant. Furthermore, FDA-approved SPRAVATO bears a boxed warning, commonly referred to as a "black box warning," which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses the risk for sedation, dissociation, and respiratory depression after administration; the potential for abuse and misuse; the increased risk of suicidal thoughts and behaviors in pediatric and young adult patients taking antidepressants; and the requirement that SPRAVATO be available only through a restricted program, the SPRAVATO REMS, because of the risks of serious adverse outcomes from sedation, dissociation, respiratory depression, abuse, and misuse. The SPRAVATO REMS requires SPRAVATO to be dispensed and administered in medically supervised health care settings that are certified in the REMS and monitor patients for a minimum of two hours following administration. In addition, pharmacies must be certified in the REMS and must only dispense SPRAVATO to health care settings that are certified in the program.Misbranded Drug ViolationsA drug is misbranded under section 502(f)(1) of the FD&C Act if its labeling fails to bear adequate directions for use. "Adequate directions for use" means directions under which a layperson can use a drug safely and for the purposes for which it is intended (see 21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1) of the FD&C Act include those that, because of their toxicity or other potentiality for harmful effect, or the method of their use, or the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act (21 U.S.C. 353(b)(1)(A)), can be used safely only at the direction, and under the supervision, of a licensed practitioner.You failed to bear adequate directions for use on the labeling for this drug product that you have introduced into interstate commerce. Because the aforementioned drug is a prescription drug intended for conditions that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use the product safely for their intended use. Consequently, the labeling for this drug product fails to bear adequate directions for use, causing it to be misbranded under section 502(f)(1) of the FD&C Act. Because this drug is not approved in the United States, it is also not exempt under 21 CFR 201.115(a) from the requirements of section 502(f)(1) of the FD&C Act. By offering this drug for sale to U.S. consumers, www.ketaminetroches.com is causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&C Act.ConclusionAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.Send your written response to FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov within 15 business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your written response with reference number “MARCS-CMS 725148” in the subject line of the email.If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.Please note FDA posts warning letters on www.fda.gov.Sincerely,/S/Sangeeta Vaswani Chatterjee, PharmDDirectorOffice of Drug Security, Integrity, and ResponseOffice of ComplianceCenter for Drug Evaluation and ResearchU.S. Food and Drug Administration_____________________________1 REMS refers to a drug safety program that FDA can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks. See the Risk Evaluation and Mitigation Strategies website at https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems.

Delivery Method:VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTEDProduct:DrugsRecipient:Ketdaxandrugs / www.ketdaxandrugs.orgUnited Statescontact@ketdaxandrugs.orgIssuing Office:Center for Drug Evaluation and Research (CDER)United StatesJune 23, 2026WARNING LETTERReference Number: MARCS-CMS 725155To Ketdaxandrugs:This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website www.ketdaxandrugs.org. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that you comply with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.As discussed below, FDA has observed that www.ketdaxandrugs.org introduces into interstate commerce unapproved and misbranded ketamine drug products, including certain drugs for which the FDA-approved version is an injectable or subject to a Risk Evaluation and Mitigation Strategy (REMS).1 FDA has identified significant risks associated with unapproved ketamine products, especially in the absence of appropriate medical supervision. Given the increased interest in the use of ketamine products, the easy availability of unapproved and misbranded ketamine products via the internet puts U.S. consumers at risk for serious adverse events. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body's natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis.There are also inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.Accordingly, FDA requests that www.ketdaxandrugs.org cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm.FDA ReviewViolations were identified and documented during a review of your website www.ketdaxandrugs.org, FDA Establishment Identifier (FEI) 3043544188, on February 26, 2026.Violations of the Federal Food, Drug, and Cosmetic ActOn your website at internet address www.ketdaxandrugs.org, you introduce into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), 301(d), 301(k), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 331(a), 331(d), 331(k), 352(f)(1), 353(b)(1), and 355(a)).The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.Unapproved New Drug ViolationsCertain products offered for sale by www.ketdaxandrugs.org are drugs within the meaning of section 201(g) of the FD&C Act (21 U.S.C. 321(g)) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body. These drugs are also new drugs as defined by section 201(p) of the FD&C Act (21 U.S.C. 321(p)), because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act.You failed to obtain approved applications pursuant to section 505 of the FD&C Act (21 U.S.C. 355) for these products that you have introduced into interstate commerce. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act.An example of an unapproved ketamine drug product you offer for sale on www.ketdaxandrugs.org is ketamine marketed as "KETAMINE CRYSTAL." Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 Code of Federal Regulations (CFR) 201.128) includes the claim "Ket is a dissociative anesthetic that was developed in the early 1960s and used in human and veterinary medicine."While there are FDA-approved versions of ketamine drug products on the market in the United States, there is no approved drug application pursuant to section 505 of the FD&C Act in effect for "KETAMINE CRYSTAL" offered by www.ketdaxandrugs.org.FDA-approved ketamine, including products marketed under the brand name KETALAR, is a Schedule III controlled substance. It is an intravenous or intramuscular injection indicated as a general anesthetic, including as a sole agent or as an adjunct to other anesthetic agents, for the induction of anesthesia and for diagnostic and surgical procedures. Ketamine is a racemic mixture consisting of two mirror image molecules, R- and S-ketamine (arketamine and esketamine, respectively). This product is only available pursuant to a prescription from a licensed practitioner. Ketamine is not FDA-approved for the treatment of any psychiatric disorder.FDA-approved esketamine, a ketamine derivative, is a Schedule III controlled substance marketed under the brand name SPRAVATO. It is a nasal spray indicated for treatment-resistant depression in adults and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in conjunction with an oral antidepressant. Furthermore, FDA-approved SPRAVATO bears a boxed warning, commonly referred to as a "black box warning," which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses the risk for sedation, dissociation, and respiratory depression after administration; the potential for abuse and misuse; the increased risk of suicidal thoughts and behaviors in pediatric and young adult patients taking antidepressants; and the requirement that SPRAVATO be available only through a restricted program, the SPRAVATO REMS, because of the risks of serious adverse outcomes from sedation, dissociation, respiratory depression, abuse, and misuse. The SPRAVATO REMS requires SPRAVATO to be dispensed and administered in medically supervised health care settings that are certified in the REMS and monitor patients for a minimum of two hours following administration. In addition, pharmacies must be certified in the REMS and must only dispense SPRAVATO to health care settings that are certified in the program.Misbranded Drug ViolationsA drug is misbranded under section 502(f)(1) of the FD&C Act if its labeling fails to bear adequate directions for use. "Adequate directions for use" means directions under which a layperson can use a drug safely and for the purposes for which it is intended (see 21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1) of the FD&C Act include those that, because of their toxicity or other potentiality for harmful effect, or the method of their use, or the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act (21 U.S.C. 353(b)(1)(A)), can be used safely only at the direction, and under the supervision, of a licensed practitioner.You failed to bear adequate directions for use on the labeling for this drug product that you have introduced into interstate commerce. Because the aforementioned drug is a prescription drug intended for conditions that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use this product safely for its intended use. Consequently, the labeling for this drug product fails to bear adequate directions for use, causing it to be misbranded under section 502(f)(1) of the FD&C Act. Because this drug is not approved in the United States, it is also not exempt under 21 CFR 201.115(a) from the requirements of section 502(f)(1) of the FD&C Act. By offering this drug for sale to U.S. consumers, www.ketdaxandrugs.org is causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&C Act.Furthermore, under U.S. law, prescription drugs can be dispensed only pursuant to a prescription from a health care practitioner licensed by law to administer prescription drugs. By offering the aforementioned drug product without requiring a prescription, www.ketdaxandrugs.org jeopardizes patient safety and misbrands the drug product under section 503(b)(1) of the FD&C Act. Dispensing a prescription drug without a prescription is an act which results in the drug being misbranded while held for sale, in violation of section 301(k) of the FD&C Act.ConclusionAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.Send your written response to FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov within 15 business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your written response with reference number “MARCS-CMS 725155” in the subject line of the email.If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.Please note FDA posts warning letters on www.fda.gov.Sincerely,/S/Sangeeta Vaswani Chatterjee, PharmDDirectorOffice of Drug Security, Integrity, and ResponseOffice of ComplianceCenter for Drug Evaluation and ResearchU.S. Food and Drug Administration__________________________1 REMS refers to a drug safety program that FDA can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks. See the Risk Evaluation and Mitigation Strategies website at https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems.

Delivery Method:VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTEDProduct:DrugsRecipient:Legit Ketamine Suppliers / www.legitketaminesuppliers.comUnited Statesinfo@legitketaminesuppliers.comIssuing Office:Center for Drug Evaluation and Research (CDER)United StatesJune 23, 2026WARNING LETTERReference Number: MARCS-CMS 725149To Legit Ketamine Suppliers:This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website www.legitketaminesuppliers.com. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that you comply with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.As discussed below, FDA has observed that www.legitketaminesuppliers.com introduces into interstate commerce unapproved and misbranded ketamine drug products, including certain drugs for which the FDA-approved version is an injectable or subject to a Risk Evaluation and Mitigation Strategy (REMS).1 FDA has identified significant risks associated with unapproved ketamine products, especially in the absence of appropriate medical supervision. Given the increased interest in the use of ketamine products, the easy availability of unapproved and misbranded ketamine products via the internet puts U.S. consumers at risk for serious adverse events. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body's natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis.There are also inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.Accordingly, FDA requests that www.legitketaminesuppliers.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm.FDA ReviewViolations were identified and documented during a review of your website www.legitketaminesuppliers.com, FDA Establishment Identifier (FEI) 3043543369, on February 26, 2026.Violations of the Federal Food, Drug, and Cosmetic ActOn your website at internet address www.legitketaminesuppliers.com, you introduce into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), 301(d), 301(k), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 331(a), 331(d), 331(k), 352(f)(1), 353(b)(1), and 355(a)).The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.Unapproved New Drug ViolationsCertain products offered for sale by www.legitketaminesuppliers.com are drugs within the meaning of section 201(g) of the FD&C Act (21 U.S.C. 321(g)) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body. These drugs are also new drugs as defined by section 201(p) of the FD&C Act (21 U.S.C. 321(p)), because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act.You failed to obtain approved applications pursuant to section 505 of the FD&C Act (21 U.S.C. 355) for these products that you have introduced into interstate commerce. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act.An example of an unapproved ketamine drug product you offer for sale on www.legitketaminesuppliers.com is ketamine marketed as "ketamine buy." Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 Code of Federal Regulations (CFR) 201.128) includes the claim "Ketamine injections are employed in treating acute and chronic pain, particularly in patients who are opioid-tolerant or who have severe, unrelieved pain. It provides pain relief without the severe respiratory depression that opioids can cause."A second example of an unapproved ketamine drug product you offer for sale on www.legitketaminesuppliers.com is esketamine marketed as "Ketamine Nasal Spray." Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 CFR 201.128) includes the claim “Ketamine nasal spray is a novel treatment primarily used for managing treatment-resistant depression (TRD) and has also shown potential in treating other mental health disorders such as anxiety . . . . "While there are FDA-approved versions of ketamine drug products on the market in the United States, there are no approved drug applications pursuant to section 505 of the FD&C Act in effect for "ketamine buy" and "Ketamine Nasal Spray" offered by www.legitketaminesuppliers.com.FDA-approved ketamine, including products marketed under the brand name KETALAR, is a Schedule III controlled substance. It is an intravenous or intramuscular injection indicated as a general anesthetic, including as a sole agent or as an adjunct to other anesthetic agents, for the induction of anesthesia and for diagnostic and surgical procedures. Ketamine is a racemic mixture consisting of two mirror image molecules, R- and S-ketamine (arketamine and esketamine, respectively). This product is only available pursuant to a prescription from a licensed practitioner. Ketamine is not FDA-approved for the treatment of any psychiatric disorder.FDA-approved esketamine, a ketamine derivative, is a Schedule III controlled substance marketed under the brand name SPRAVATO. It is a nasal spray indicated for treatment-resistant depression in adults and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in conjunction with an oral antidepressant. Furthermore, FDA-approved SPRAVATO bears a boxed warning, commonly referred to as a "black box warning," which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses the risk for sedation, dissociation, and respiratory depression after administration; the potential for abuse and misuse; the increased risk of suicidal thoughts and behaviors in pediatric and young adult patients taking antidepressants; and the requirement that SPRAVATO be available only through a restricted program, the SPRAVATO REMS, because of the risks of serious adverse outcomes from sedation, dissociation, respiratory depression, abuse, and misuse. The SPRAVATO REMS requires SPRAVATO to be dispensed and administered in medically supervised health care settings that are certified in the REMS and monitor patients for a minimum of two hours following administration. In addition, pharmacies must be certified in the REMS and must only dispense SPRAVATO to health care settings that are certified in the program.Misbranded Drug ViolationsA drug is misbranded under section 502(f)(1) of the FD&C Act if its labeling fails to bear adequate directions for use. "Adequate directions for use" means directions under which a layperson can use a drug safely and for the purposes for which it is intended (see 21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1) of the FD&C Act include those that, because of their toxicity or other potentiality for harmful effect, or the method of their use, or the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act (21 U.S.C. 353(b)(1)(A)), can be used safely only at the direction, and under the supervision, of a licensed practitioner.You failed to bear adequate directions for use on the labeling for these drug products that you have introduced into interstate commerce. Because the aforementioned drugs are prescription drugs intended for conditions that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use the products safely for their intended use. Consequently, the labeling for these drug products fails to bear adequate directions for use, causing them to be misbranded under section 502(f)(1) of the FD&C Act. Because these drugs are not approved in the United States, they are also not exempt under 21 CFR 201.115(a) from the requirements of section 502(f)(1) of the FD&C Act. By offering these drugs for sale to U.S. consumers, www.legitketaminesuppliers.com is causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&C Act.Furthermore, under U.S. law, prescription drugs can be dispensed only pursuant to a prescription from a health care practitioner licensed by law to administer prescription drugs. By offering the aforementioned drug products without requiring a prescription, www.legitketaminesuppliers.com jeopardizes patient safety and misbrands the drug products under section 503(b)(1) of the FD&C Act. Dispensing a prescription drug without a prescription is an act which results in the drug being misbranded while held for sale, in violation of section 301(k) of the FD&C Act.ConclusionAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.Send your written response to FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov within 15 business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your written response with reference number “MARCS-CMS 725149” in the subject line of the email.If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.Please note FDA posts warning letters on www.fda.gov.Sincerely,/S/Sangeeta Vaswani Chatterjee, PharmDDirectorOffice of Drug Security, Integrity, and ResponseOffice of ComplianceCenter for Drug Evaluation and ResearchU.S. Food and Drug Administration___________________________1 REMS refers to a drug safety program that FDA can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks. See the Risk Evaluation and Mitigation Strategies website at https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems.

Delivery Method:VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTEDProduct:DrugsRecipient:All Ketamine HCL / www.allketaminehcl.comUnited Statessupport@allketaminehcl.comIssuing Office:Center for Drug Evaluation and Research (CDER)United StatesJune 23, 2026WARNING LETTERReference Number: MARCS-CMS 725150To All Ketamine HCL:This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website www.allketaminehcl.com. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that you comply with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.As discussed below, FDA has observed that www.allketaminehcl.com introduces into interstate commerce unapproved and misbranded ketamine drug products, including certain drugs for which the FDA-approved version is an injectable or subject to a Risk Evaluation and Mitigation Strategy (REMS).1 FDA has identified significant risks associated with unapproved ketamine products, especially in the absence of appropriate medical supervision. Given the increased interest in the use of ketamine products, the easy availability of unapproved and misbranded ketamine products via the internet puts U.S. consumers at risk for serious adverse events. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body's natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis.There are also inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.Accordingly, FDA requests that www.allketaminehcl.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm.FDA ReviewViolations were identified and documented during a review of your website www.allketaminehcl.com, FDA Establishment Identifier (FEI) 3043544156, on February 27, 2026.Violations of the Federal Food, Drug, and Cosmetic ActOn your website at internet address www.allketaminehcl.com, you introduce into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), 301(d), 301(k), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 331(a), 331(d), 331(k), 352(f)(1), 353(b)(1), and 355(a)).The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.Unapproved New Drug ViolationsCertain products offered for sale by www.allketaminehcl.com are drugs within the meaning of section 201(g) of the FD&C Act (21 U.S.C. 321(g)) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body. These drugs are also new drugs as defined by section 201(p) of the FD&C Act (21 U.S.C. 321(p)), because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act.You failed to obtain approved applications pursuant to section 505 of the FD&C Act (21 U.S.C. 355) for these products that you have introduced into interstate commerce. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act.An example of an unapproved ketamine drug product you offer for sale on www.allketaminehcl.com is ketamine marketed as "Ketamax." Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 Code of Federal Regulations (CFR) 201.128) includes the claim "Ketamax 50mg is an anesthetic medication. Ketamax is used to put you to sleep for surgery and to prevent pain and discomfort during certain medical tests or procedures."While there are FDA-approved versions of ketamine drug products on the market in the United States, there is no approved drug application pursuant to section 505 of the FD&C Act in effect for "Ketamax" offered by www.allketaminehcl.com.FDA-approved ketamine, including products marketed under the brand name KETALAR, is a Schedule III controlled substance. It is an intravenous or intramuscular injection indicated as a general anesthetic, including as a sole agent or as an adjunct to other anesthetic agents, for the induction of anesthesia and for diagnostic and surgical procedures. Ketamine is a racemic mixture consisting of two mirror image molecules, R- and S-ketamine (arketamine and esketamine, respectively). This product is only available pursuant to a prescription from a licensed practitioner. Ketamine is not FDA-approved for the treatment of any psychiatric disorder.FDA-approved esketamine, a ketamine derivative, is a Schedule III controlled substance marketed under the brand name SPRAVATO. It is a nasal spray indicated for treatment-resistant depression in adults and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in conjunction with an oral antidepressant. Furthermore, FDA-approved SPRAVATO bears a boxed warning, commonly referred to as a "black box warning," which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses the risk for sedation, dissociation, and respiratory depression after administration; the potential for abuse and misuse; the increased risk of suicidal thoughts and behaviors in pediatric and young adult patients taking antidepressants; and the requirement that SPRAVATO be available only through a restricted program, the SPRAVATO REMS, because of the risks of serious adverse outcomes from sedation, dissociation, respiratory depression, abuse, and misuse. The SPRAVATO REMS requires SPRAVATO to be dispensed and administered in medically supervised health care settings that are certified in the REMS and monitor patients for a minimum of two hours following administration. In addition, pharmacies must be certified in the REMS and must only dispense SPRAVATO to health care settings that are certified in the program.Misbranded Drug ViolationsA drug is misbranded under section 502(f)(1) of the FD&C Act if its labeling fails to bear adequate directions for use. "Adequate directions for use" means directions under which a layperson can use a drug safely and for the purposes for which it is intended (see 21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1) of the FD&C Act include those that, because of their toxicity or other potentiality for harmful effect, or the method of their use, or the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act (21 U.S.C. 353(b)(1)(A)), can be used safely only at the direction, and under the supervision, of a licensed practitioner.You failed to bear adequate directions for use on the labeling for this drug product that you have introduced into interstate commerce. Because the aforementioned drug is a prescription drug intended for conditions that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use this product safely for its intended use. Consequently, the labeling for this drug product fails to bear adequate directions for use, causing it to be misbranded under section 502(f)(1) of the FD&C Act. Because this drug is not approved in the United States, it is also not exempt under 21 CFR 201.115(a) from the requirements of section 502(f)(1) of the FD&C Act. By offering this drug for sale to U.S. consumers, www.allketaminehcl.com is causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&C Act.Furthermore, under U.S. law, prescription drugs can be dispensed only pursuant to a prescription from a health care practitioner licensed by law to administer prescription drugs. By offering the aforementioned drug product without requiring a prescription, www.allketaminehcl.com jeopardizes patient safety and misbrands the drug product under section 503(b)(1) of the FD&C Act. Dispensing a prescription drug without a prescription is an act which results in the drug being misbranded while held for sale, in violation of section 301(k) of the FD&C Act.ConclusionAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.Send your written response to FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov within 15 business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your written response with reference number “MARCS-CMS 725150” in the subject line of the email.If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.Please note FDA posts warning letters on www.fda.gov.Sincerely,/S/Sangeeta Vaswani Chatterjee, PharmDDirectorOffice of Drug Security, Integrity, and ResponseOffice of ComplianceCenter for Drug Evaluation and ResearchU.S. Food and Drug Administration__________________1 REMS refers to a drug safety program that FDA can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks. See the Risk Evaluation and Mitigation Strategies website at https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems.